Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Zinc sulphate for viral warts: reply from authors (2003)
    Oxford, UK : Blackwell Science Ltd
    British journal of dermatology 148 (2003), S. 0 
    Details
    ISSN: 1365-2133
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1365-2133.2003.05361.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial (2002)
    Oxford, UK : Blackwell Science Ltd
    British journal of dermatology 146 (2002), S. 0 
    Details
    ISSN: 1365-2133
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Background  Viral warts are common dermatological diseases; although the rate of spontaneous recovery is high, it usually takes a long time, and some patients might not show this spontaneous healing. Zinc has an important effect on the immune system and it has been used as an immunomodulator to treat a variety of skin disorders. Objective To assess whether oral zinc was effective in treating viral warts of patients evaluated between May 1999 and April 2000. Patients and methods This was a placebo-controlled clinical trial. Eighty patients with viral warts (common, plantar and plane) were all resistant to all forms of treatment. Each patient had 〉 15 warts. Forty patients were treated by oral zinc sulphate at a dose of 10 mg kg−1 daily up to 600 mg day−1 and followed-up for resolution of their warts and for any evidence of recurrence for 2–6 months. Another 40 patients were given a placebo oral treatment in the form of glucose, and followed-up for the same period. Results Only 23 patients of the first group (zinc treated) and 20 patients of the second group (placebo treated) completed the study. In all patients the serum level of zinc was low. In the zinc-treated group, the overall response was complete clearance of warts observed in 20 patients (86·9%) after 2 months of treatment. Fourteen patients (60·9%) showed complete disappearance of their warts after 1 month. Three patients (13·3%) failed to respond to the treatment after 2 months of therapy. The response to treatment was directly related to the increment in serum zinc level. No patient of the placebo-treated group showed any response. Conclusions We conclude that zinc sulphate at a dose of 10 mg kg−1 daily seems to be a highly efficacious therapeutic option for recalcitrant viral warts and proved to be safe with few adverse effects.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1046/j.1365-2133.2002.04617.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Trimethylaminuria: The detection of carriers using a trimethylamine load test (1989)
    Springer
    Journal of inherited metabolic disease 12 (1989), S. 80-85 
    Details
    ISSN: 1573-2665
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A method potentially of value for investigating putative heterozygotes or carriers of trimethylaminuria by using a single oral dose of trimethylamine (TMA) is described. For healthy volunteers under normal dietary condition and following oral challenge with 300 mg and 600 mg TMA-base, over 90% of the urinary TMA was excreted in the form of TMA (93.6 ± 1.6%). However, at a dose level of 900 mg TMA-base, there was clear evidence of saturation of theN-oxidation reaction as urinary TMA excretion declined to 77.2% (range 74.8–78.9) of the total dose of TMA. By contrast, in pedigree studies based upon propositi with trimethylaminuria, several parents were identified who showed clear evidence of saturation of theN-oxidation of TMA at the 600 mg TMA-base dose level, but not at 300 mg TMA-base or under normal dietary condition. In these individuals, the proportion of urinary TMA as trimethylamineN-oxide (TMAO) declined to (77.3 ± 1.7%). Accordingly we propose that the oral administration of 600 mg TMA-base and the analysis of the following 0–8-h urine collection may be useful for the investigation of possible carriers of trimethylaminuria.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01805534
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...